The aim of the study is to assess the efficacy of fenofibrate in either reversing and/or
preventing the development of PIPN in breast cancer patients treated with paclitaxel-based
regimen. The primary outcome :clinical improvement of neuropathic pain and grade by
1-CT-CTCAE -VERSION-4 & FACT/GOG-NT-12 questionnaire and its effect on quality of life (QOL).
The secondary outcome : the efficacy of fenofibrate in either reversing and/or preventing the
development of PIPN via alteration of either Nerve growth factor (NGF) or/ and/( NFL).